Bayer Presents 13 Stroke Research Abstracts at ESOC 2026, Including Asundexian Phase III Trial Data

Key Takeaways

• Bayer presents 13 abstracts from its stroke franchise at the European Stroke Organisation Conference (ESOC) 2026
• Two late-breaking presentations feature new analyses from the Phase III OCEANIC-STROKE trial of Asundexian
• Data includes insights on ischemic strokes during the trial and net clinical benefit analysis for stroke prevention

---

Bayer Showcases Comprehensive Stroke Research Portfolio at ESOC 2026

Bayer announced it will present 13 research abstracts from its stroke franchise at the European Stroke Organisation Conference (ESOC) 2026, with particular focus on two late-breaking analyses from the Phase III OCEANIC-STROKE trial evaluating Asundexian for stroke prevention.

OCEANIC-STROKE Trial Takes Center Stage

The landmark OCEANIC-STROKE study represents a significant advancement in stroke prevention research. The two late-breaking presentations will provide crucial insights into ischemic strokes that occurred during the trial period, offering researchers and clinicians valuable data on stroke patterns and prevention strategies.

Additionally, the net clinical benefit analysis from the trial will help determine the overall risk-benefit profile of Asundexian, potentially informing future treatment guidelines for stroke prevention.

Comprehensive Stroke Research Portfolio

Beyond the OCEANIC-STROKE data, Bayer’s presentation portfolio at ESOC 2026 will include analyses of intracranial hemorrhage and predictors of recurrent stroke events. This comprehensive approach demonstrates the company’s commitment to addressing multiple aspects of stroke care and prevention.

Market and Clinical Implications

The presentation of 13 abstracts positions Bayer as a significant contributor to stroke research and treatment development. The OCEANIC-STROKE trial data, in particular, could influence clinical practice guidelines and provide new options for patients at risk of stroke.

Stroke remains a leading cause of death and disability worldwide, making advances in prevention and treatment critically important for public health. The data presented at ESOC 2026 may offer new insights into optimizing stroke prevention strategies and improving patient outcomes.

Looking Forward

The European Stroke Organisation Conference serves as a premier platform for sharing cutting-edge stroke research. Bayer’s substantial presence at the conference underscores the company’s ongoing investment in neurological research and development, particularly in the stroke prevention space where significant unmet medical needs remain.

---

Frequently Asked Questions

What is Asundexian and how does it work for stroke prevention?

Asundexian is an investigational drug being studied in the Phase III OCEANIC-STROKE trial for stroke prevention. The specific mechanism and efficacy data will be revealed through the trial results presented at ESOC 2026.

When will Asundexian be available for patients?

Asundexian is currently in Phase III clinical trials. Availability will depend on trial results, regulatory review, and approval processes, which typically take several years to complete.

How significant is presenting 13 abstracts at a major conference?

Presenting 13 abstracts at ESOC demonstrates substantial research activity and investment in stroke care. It positions Bayer as a major contributor to stroke research and suggests a robust pipeline of potential treatments.

Related coverage

• BioNTech doses first patient in Phase 1 pancreatic cancer mRNA vaccine trial
• MariTide Phase 2 obesity data show up to 20% weight loss at one year
• Moderna mRNA-1083 Phase 3 data show stronger flu and COVID immune response